# Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders

> **NCT00358657** · PHASE2 · TERMINATED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 14 (actual)

## Conditions studied

- Immunodeficiency Syndrome
- Severe Aplastic Anemia
- Genetic Disorder

## Interventions

- **PROCEDURE:** Allogeneic Bone Marrow Transplantation
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine Phosphate
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Mycophenolate Mofetil
- **PROCEDURE:** Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation
- **DRUG:** Sirolimus
- **DRUG:** Tacrolimus
- **RADIATION:** Total-Body Irradiation

## Key facts

- **NCT ID:** NCT00358657
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-05-24
- **Primary completion:** 2018-08-17
- **Final completion:** 2019-05-25
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2021-01-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00358657

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00358657, "Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00358657. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*